AbbVie (ABBV)
(Delayed Data from NYSE)
$201.20 USD
-0.48 (-0.24%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $201.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum C VGM
AbbVie (ABBV) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$209.00 | $240.00 | $170.00 | 3.88% |
Price Target
Based on short-term price targets offered by 24 analysts, the average price target for AbbVie comes to $208.29. The forecasts range from a low of $170.00 to a high of $240.00. The average price target represents an increase of 3.28% from the last closing price of $201.68.
Analyst Price Targets (26)
Broker Rating
AbbVie currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 26 brokerage firms. The current ABR compares to an ABR of 1.67 a month ago based on 23 recommendations.
Of the 26 recommendations deriving the current ABR, 16 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 61.54% and 7.69% of all recommendations. A month ago, Strong Buy made up 60.87%, while Buy represented 8.7%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 17 | 15 | 14 | 14 | 14 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 8 | 8 | 7 | 7 | 7 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.65 | 1.70 | 1.67 | 1.67 | 1.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
11/4/2024 | Argus Research Corp. | David A Toung | Not Available | Strong Buy |
10/31/2024 | Raymond James | Gary Nachman | Moderate Buy | Moderate Buy |
10/31/2024 | UBS | Trung Huynh | Hold | Hold |
10/30/2024 | Not Identified | Not Identified | Hold | Hold |
10/25/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
10/24/2024 | Berenberg Bank | Luisa Hector | Hold | Hold |
10/17/2024 | Not Identified | Not Identified | Not Available | Hold |
10/17/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
10/9/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
10/7/2024 | Cowen & Co. | Steve M Scala | Strong Buy | Strong Buy |
9/16/2024 | Not Identified | Not Identified | Hold | Hold |
8/30/2024 | William Blair | Matt Phipps | Not Available | Strong Buy |
8/28/2024 | SVB Securities | David Risinger | Hold | Hold |
8/1/2024 | Daiwa America | Narumi Nakagiri | Not Available | Strong Buy |
7/30/2024 | Evercore Partners | Gavin Clark-Gartner | Strong Buy | Strong Buy |
7/26/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
7/26/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/10/2024 | Atlantic Equities | Steven K Chesney | Strong Buy | Strong Buy |
6/28/2024 | Goldman Sachs | Chris Shibutani | Strong Buy | Strong Buy |
6/5/2024 | Not Identified | Not Identified | Hold | Strong Buy |
3/22/2024 | Guggenheim Securities | Vamil Divan | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.65 |
ABR (Last week) | 1.70 |
# of Recs in ABR | 27 |
Average Target Price | $209.00 |
LT Growth Rate | 7.50% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 86 of 252 |
Current Quarter EPS Est: | 2.99 |
ABBV FAQs
AbbVie Inc. (ABBV) currently has an average brokerage recommendation (ABR) of 1.65 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 27 brokerage firms.
The average price target for AbbVie Inc. (ABBV) is $209.00. The current on short-term price targets is based on 13 reports.
The forecasts for AbbVie Inc. (ABBV) range from a low of $170 to a high of $240. The average price target represents a increase of $3.88 from the last closing price of $201.20.
The current UPSIDE for AbbVie Inc. (ABBV) is 3.88%
Based on short-term price targets offered by 24 analysts, the average price target for AbbVie comes to $208.29. The forecasts range from a low of $170.00 to a high of $240.00. The average price target represents an increase of 3.28% from the last closing price of $201.68.